In the lab, antibodies produced during an Omicron infection protected against Delta. If Omicron dominates in the real world, that could lead to a less dire future.
Author: CARL ZIMMER
Novavax’s Covid Vaccine Is Authorized in Europe
The vaccine will be the fifth to become available in the E.U., which already has ample supplies.
New ‘Omicron’ Variant Stokes Concern but Vaccines May Still Work
The Omicron variant carries worrisome mutations that may let it evade antibodies, scientists said. But it will take more research to know how it fares against vaccinated people.
Mix-and-Match Covid Boosters: Why They Just Might Work
The F.D.A. may authorize booster shots of vaccines different from the ones that Americans originally received. The science behind the move is promising.
Newly Discovered Bat Viruses Give Hints to Covid’s Origins
Coronaviruses discovered in Laotian bats are surprisingly adept at infecting human cells, showing that such deadly features can indeed evolve outside of a lab.
Pfizer’s Shot Still Strong Against Covid. Israeli Data Raise Prospect of Waning Against Infection.
Because of a small sample size and other factors, a large range of uncertainties flank the new findings. The vaccine’s strength against severe disease remains high.
Mixing Pfizer, AstraZeneca Vaccines Gives Strong Covid Protection, Study Finds
Administering a first dose of one vaccine and a second dose of the other, in either order, is likely to provide potent protection, the researchers said.
Scientist Finds Early Coronavirus Sequences That Had Been Mysteriously Deleted
By rooting through files stored on Google Cloud, a researcher says he recovered 13 early coronavirus sequences that had disappeared from a database last year.
Scientist Finds Early Virus Sequences That Had Been Mysteriously Deleted
By rooting through files stored on Google Cloud, a researcher says he recovered 13 early coronavirus sequences that had disappeared from a database last year.
CureVac’s Covid-19 Vaccine Disappoints in Clinical Trial
A preliminary analysis showed that CureVac’s mRNA vaccine had an efficacy of just 47 percent. “This is pretty devastating for them,” one expert said.